Alpha Tau Medical (DRTS) FDA Approvals $12.76 -0.72 (-5.30%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Alpha Tau Medical's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Alpha Tau Medical (DRTS). Over the past two years, Alpha Tau Medical has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Alpha. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Alpha DaRT FDA Regulatory Timeline and Events Alpha DaRT is a drug developed by Alpha Tau Medical for the following indication: Prostate cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA approved - October 19,2026Fda Approved Investigational Device ExemptionDrug: Alpha DaRTAnnounced Date: October 19, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial.Read AnnouncementEnrollment Update - June 11,2026Enrollment Update Drug: Alpha DaRTAnnounced Date: June 11, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company to proceed with enrollment of the final seven patients in its U.S. REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial, following the FDA's review of a pre-specified interim safety report of the first three patients treated in the trial.AI SummaryAlpha Tau Medical said the U.S. Food and Drug Administration cleared it to move ahead with enrollment of the final seven patients in its U.S. REGAIN trial for recurrent glioblastoma. The decision came after the FDA reviewed a planned interim safety report from the first three patients treated. The company said it will restart recruitment right away because doctors want to treat patients as quickly as possible. The trial now includes two more leading U.S. academic cancer centers, which should expand access across the country and add more neuro-oncology expertise. Alpha Tau said Alpha DaRT may offer a new option for patients with recurrent glioblastoma, a disease with about 14,000 new U.S. cases each year and very limited treatment choices. The company described the move as an important step toward testing a potentially transformative therapy for a cancer with poor outcomes after recurrence.Read AnnouncementPositive Results - June 1,2026Positive Results Phase 1/2Drug: Alpha DaRTAnnounced Date: June 1, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced positive overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).AI SummaryAlpha Tau Medical said a pooled analysis of three Phase I/II studies showed encouraging overall survival and safety results for its Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. The therapy is given by endoscopic ultrasound and is designed as a one-time, minimally invasive treatment placed directly into the tumor. In patients who had already received first-line chemotherapy, median overall survival was 11.2 months in metastatic disease and 11.1 months in locally advanced disease, which compares favorably with historical results for later-line care. The company also reported a favorable safety profile, with treatment-related side effects in 36% of patients and serious side effects in 9%, while no treatment-related deaths or lasting toxicity were seen. These results support Alpha DaRT’s potential as a local treatment that may fit into the patient journey without adding major systemic burden.Read AnnouncementGroundbreaking update - May 11,2026Groundbreaking Update Drug: Alpha DaRTAnnounced Date: May 11, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced groundbreaking interim data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial.AI SummaryAlpha Tau Medical announced interim results from the REGAIN U.S. trial of Alpha DaRT for recurrent glioblastoma. In the first three patients treated at The Ohio State University Comprehensive Cancer Center, two achieved complete responses with total disappearance of all enhancing tumor lesions on multiple MRI scans. One grade 3 serious adverse event was reported but has since resolved. The procedures were performed by a multidisciplinary team led by principal investigator Joshua D. Palmer, MD, with medical physicist Michael Degnan, MS, DABR, and neurosurgeon J. Bradley Elder, MD, using a novel intracranial delivery approach designed by Alpha Tau. The REGAIN study is a prospective, open-label, single-arm trial evaluating the feasibility and safety of Alpha DaRT for recurrent GBM. The company noted that glioblastoma is highly aggressive and treatment-resistant, with an average survival of about eight months per the National Brain Tumor Society. Alpha Tau will hold a conference call with Dr. Palmer and management on May 11, 2026, at 8:30 am ET to discuss the data.Read AnnouncementEnrollment Update - May 8,2026Enrollment Update Drug: Alpha DaRTAnnounced Date: May 8, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced the completion of enrollment in its ReSTART pivotal trial (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), a U.S. multicenter study evaluating the efficacy and safety of intratumoral Alpha DaRT for the treatment of patients with recurrent cutaneous squamous cell carcinoma (cSCC).AI SummaryAlpha Tau Medical Ltd. completed enrollment of 88 patients in ReSTART, a U.S. multicenter pivotal trial testing intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC). Completion shifts the study from recruitment to patient follow-up and data maturation, a key step toward assessing safety and effectiveness. Alpha DaRT inserts short-lived alpha-emitting sources directly into tumors. The particles act over very short distances, aiming to destroy cancer cells while sparing nearby healthy tissue. A pivotal trial is designed to provide the definitive clinical evidence regulators rely on. ReSTART builds on earlier skin cancer studies in Israel, Italy, France and the U.S. cSCC is the second most common skin cancer and is harder to treat when surgery and standard therapies fail. Alpha Tau, founded in 2016, focuses on developing Alpha DaRT for solid tumors and will now follow patients and analyze outcomes.Read AnnouncementPresentation - May 4,2026Presentation Drug: Alpha DaRTAnnounced Date: May 4, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced the presentation of updated pooled results from two first-in-human clinical trials of Alpha DaRT in pancreatic ductal adenocarcinoma (PDAC) at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference.AI SummaryAlpha Tau Medical Ltd. presented pooled results from two first-in-human trials of Alpha DaRT in pancreatic ductal adenocarcinoma (PDAC) at Digestive Disease Week (DDW) 2026. The oral presentation marked the therapy’s first showing at a leading international gastroenterology conference. The pooled analysis showed a 100% local disease control rate in evaluable patients. Safety was favorable: among 26 treated subjects there were eight device-related adverse events in seven patients (27%), and all but one case (lingering fatigue) resolved within two weeks. Patients were highly heterogeneous and heavily pre-treated, including some ineligible for chemotherapy and others who had received up to four prior lines. Alpha DaRT is delivered via a streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed to fit standard GI endoscopy workflows. These initial human results suggest potential for patients with limited options and support further clinical study.Read AnnouncementProvided Update - April 27,2026Provided Update Drug: Alpha DaRTAnnounced Date: April 27, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced that an abstract entitled "Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer" has been accepted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026. .AI SummaryAlpha Tau Medical Ltd. announced that an abstract titled "Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer" was accepted for presentation at the 2026 ASCO Annual Meeting, May 29–June 2, 2026. The pooled analysis reports safety and efficacy data from 58 patients enrolled in three prospective clinical studies conducted at centers in Canada and Israel. The abstract will be posted on the ASCO conference website on May 21, 2026 at 5:00 PM ET. The acceptance follows Alpha Tau presentations this year at the ASCO Gastrointestinal Cancers Symposium and Digestive Disease Week, signaling growing scientific interest in the company’s pancreatic cancer data. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an intratumoral alpha-emitter approach designed to deliver highly localized radiation to tumors while sparing nearby healthy tissue. Alpha Tau is developing this technology for the treatment of solid tumors. Read AnnouncementProvided Update - April 23,2026Provided Update Drug: Alpha DaRTAnnounced Date: April 23, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced the successful treatment of the first patient in ACAPELLA (Alpha DaRT for CAncer of the PancrEas in Locally advanced Adenocarcinoma), the Company's European multicenter clinical trial evaluating Alpha DaRT combined with capecitabine for patients with inoperable locally advanced pancreatic ductal adenocarcinoma (LAPC) who have completed first-line mFOLFIRINOX chemotherapy..AI SummaryAlpha Tau Medical Ltd announced the successful treatment of the first patient in ACAPELLA, its European multicenter trial testing Alpha DaRT combined with capecitabine for people with inoperable, locally advanced pancreatic ductal adenocarcinoma (LAPC) who have completed first-line mFOLFIRINOX chemotherapy. Alpha DaRT delivers short-range alpha radiation from tiny radioactive sources implanted directly into the tumor using a minimally invasive technique. In ACAPELLA, Alpha DaRT is being given alongside oral capecitabine to see if the combination can better control tumors that cannot be removed by surgery. This first treatment marks the start of enrollment activity in the trial and is an early step toward evaluating safety, tolerability, and initial signals of effectiveness. The study is part of Alpha Tau’s broader effort to develop new local therapies for pancreatic cancer, a disease with limited treatment options and high unmet need. Follow-up will monitor tumor response and side effects over time. Read AnnouncementAbstract - March 31,2026Abstract Drug: Alpha DaRTAnnounced Date: March 31, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference.AI SummaryAlpha Tau Medical Ltd. announced that an abstract reporting results from two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. The acceptance means the company's data will be shared in a main session at the global gastroenterology meeting May 2–5, 2026. The trials evaluated Alpha DaRT, Alpha Tau's targeted radiotherapy technology for solid tumors, and the oral slot suggests the findings are notable for clinicians and researchers. Alpha Tau, founded in 2016 in Israel, develops Alpha DaRT, which uses radioactive sources to treat tumors. Presenting at DDW gives the company exposure to specialists in gastroenterology, oncology and surgery and may help inform clinical practice and future research for pancreatic cancer — a disease with limited treatment options. Details of the trial outcomes will be revealed at the DDW presentation.Read AnnouncementResults - January 6,2026Results Drug: Alpha DaRTAnnounced Date: January 6, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC).AI SummaryAlpha Tau Medical released final results from its first-in-human pancreatic cancer study in Montreal testing Alpha DaRT for pancreatic ductal adenocarcinoma (PDAC). In 32 patients (stage II–IV, many previously treated), Alpha DaRT delivered by endoscopic ultrasound was feasible and well tolerated. The trial showed a 22% objective response rate (ORR) and an 81% disease control rate (DCR); excluding the first two low-dose safety patients, ORR was 23% and DCR 87%. Results are published as abstracts and will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. In 23 patients with complete lab data, investigators saw no significant change one month after treatment in neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, CD4/CD8 T-cell ratio, or C-reactive protein, suggesting immune preservation versus typical radiation. IL-6 levels dropped dramatically (p<0.000001), indicating a possible anti-inflammatory effect. Alpha DaRT is now being studied with first-line chemotherapy in the U.S. multi-center IMPACT pilot trial (NCT06698458) for newly diagnosed unresectable or metastatic pancreatic cancer.Read AnnouncementProvided Update - January 5,2026Provided Update Drug: Alpha DaRTAnnounced Date: January 5, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA's previous decision to allow the Company to use the more flexible modular approach.AI SummaryAlpha Tau Medical announced it submitted the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration for Alpha DaRT, its alpha-radiation therapy. The application seeks approval for treating recurrent cutaneous squamous cell carcinoma in patients who cannot have surgery or standard radiation and who have no curative systemic options. This initial module focuses on the required non-clinical study documentation. The FDA allowed Alpha Tau to use a modular PMA framework, which lets the company submit sections of the application over time. Alpha Tau says this flexible approach can enable ongoing FDA review and earlier feedback on each module, potentially speeding and clarifying the path toward authorization. The module was filed while Alpha Tau is running its ReSTART pivotal trial for recurrent cSCC. The company expects to finish recruiting patients for that study in the first quarter of 2026.Read AnnouncementFDA approved - December 2,2025Fda Approved Drug: Alpha DaRTAnnounced Date: December 2, 2025Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with locally recurrent prostate cancer using the Company's Alpha DaRT technology.AI SummaryAlpha Tau Medical announced that the FDA has approved an Investigational Device Exemption (IDE) to start a U.S. pilot study using its Alpha DaRT technology to treat patients with locally recurrent prostate cancer. The company said the study will test Alpha DaRT as a focused local salvage therapy that could be an alternative to systemic androgen deprivation therapy. The trial plans to enroll up to 12 U.S. patients who have biochemical recurrence by the Phoenix definition (a PSA rise of 2 ng/mL from the PSA nadir). The primary goal is to evaluate safety, and secondary goals include assessing efficacy by biochemical and clinical measures of disease progression and overall survival. Alpha DaRT delivers radium-224–impregnated sources directly into tumors. Short-lived decay products emit high-energy alpha particles over very short distances, aiming to destroy tumor cells while limiting damage to nearby healthy tissue.Read AnnouncementFDA Approval - April 2,2025Fda Approval Drug: Alpha DaRTAnnounced Date: April 2, 2025Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.AI SummaryAlpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) for a pilot study using its Alpha DaRT technology to treat patients with recurrent glioblastoma, an aggressive type of brain cancer. This new approach is aimed at patients whose tumors are not suitable for surgery and who have already received central nervous system radiation. The IDE approval enables the clinical trial to enroll up to ten U.S. patients and will focus on assessing the feasibility and safety of implanting the Alpha DaRT sources directly into the tumor. The Alpha DaRT method works by delivering radium-224 inside the tumor, allowing its decay to release high-energy alpha particles that target cancer cells while sparing healthy tissue. This pilot study marks an important step toward offering a new treatment option for patients facing the poor survival outcomes associated with recurrent glioblastoma.Read AnnouncementFDA Approval - February 3,2025Fda Approval IDE ApplicationDrug: Alpha DaRTAnnounced Date: February 3, 2025Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients.AI SummaryAlpha Tau Medical Ltd recently announced that the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplement. This supplement allows the company to expand its clinical trial for treating pancreatic cancer by combining its alpha-radiation therapy, Alpha DaRT®, with first-line chemotherapy. Originally, the clinical study focused on 12 patients with newly diagnosed metastatic pancreatic cancer. With the new FDA approval, the trial will now include an additional cohort of patients with locally advanced pancreatic cancer. Each cohort will be increased to 15 patients, resulting in a total of 30 patients across up to 10 U.S. clinical trial sites. This expansion brings Alpha Tau one step closer to studying the potential benefits of its innovative treatment across a broader range of pancreatic cancer patients.Read Announcement Alpha Tau Medical FDA Events - Frequently Asked Questions Has Alpha Tau Medical received FDA approval? As of now, Alpha Tau Medical (DRTS) has not received any FDA approvals for its therapy in the last two years. What drugs has Alpha Tau Medical submitted to the FDA? In the past two years, Alpha Tau Medical (DRTS) has reported FDA regulatory activity for Alpha DaRT. What is the most recent FDA event for Alpha Tau Medical? The most recent FDA-related event for Alpha Tau Medical occurred on October 19, 2026, involving Alpha DaRT. The update was categorized as "FDA approved," with the company reporting: "Alpha Tau Medical Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial." What conditions do Alpha Tau Medical's current drugs treat? Currently, Alpha Tau Medical has one therapy (Alpha DaRT) targeting the following condition: Prostate cancer. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Arbutus Biopharma FDA EventsAcumen Pharmaceuticals FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsDiaMedica Therapeutics FDA EventsGilead Sciences FDA EventsSCYNEXIS FDA EventsSciSparc FDA EventsAbbVie FDA EventsMedtronic FDA EventsTeleflex FDA EventsAchieve Life Sciences FDA EventsBioCryst Pharmaceuticals FDA EventsHeartBeam FDA EventsCardiff Oncology FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Pulse Biosciences FDA Events TransMedics Group FDA Events AxoGen FDA Events Establishment Labs FDA Events NovoCure FDA Events PROCEPT BioRobotics FDA Events Delcath Systems FDA Events Tactile Systems Technology FDA Events SS Innovations International FDA Events Sight Sciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:DRTS last updated on 10/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s Next Partnership: Buy This Stock NowElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpha Tau Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approved - October 19,2026Fda Approved Investigational Device ExemptionDrug: Alpha DaRTAnnounced Date: October 19, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial.Read Announcement
Enrollment Update - June 11,2026Enrollment Update Drug: Alpha DaRTAnnounced Date: June 11, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company to proceed with enrollment of the final seven patients in its U.S. REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial, following the FDA's review of a pre-specified interim safety report of the first three patients treated in the trial.AI SummaryAlpha Tau Medical said the U.S. Food and Drug Administration cleared it to move ahead with enrollment of the final seven patients in its U.S. REGAIN trial for recurrent glioblastoma. The decision came after the FDA reviewed a planned interim safety report from the first three patients treated. The company said it will restart recruitment right away because doctors want to treat patients as quickly as possible. The trial now includes two more leading U.S. academic cancer centers, which should expand access across the country and add more neuro-oncology expertise. Alpha Tau said Alpha DaRT may offer a new option for patients with recurrent glioblastoma, a disease with about 14,000 new U.S. cases each year and very limited treatment choices. The company described the move as an important step toward testing a potentially transformative therapy for a cancer with poor outcomes after recurrence.Read Announcement
Positive Results - June 1,2026Positive Results Phase 1/2Drug: Alpha DaRTAnnounced Date: June 1, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced positive overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).AI SummaryAlpha Tau Medical said a pooled analysis of three Phase I/II studies showed encouraging overall survival and safety results for its Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. The therapy is given by endoscopic ultrasound and is designed as a one-time, minimally invasive treatment placed directly into the tumor. In patients who had already received first-line chemotherapy, median overall survival was 11.2 months in metastatic disease and 11.1 months in locally advanced disease, which compares favorably with historical results for later-line care. The company also reported a favorable safety profile, with treatment-related side effects in 36% of patients and serious side effects in 9%, while no treatment-related deaths or lasting toxicity were seen. These results support Alpha DaRT’s potential as a local treatment that may fit into the patient journey without adding major systemic burden.Read Announcement
Groundbreaking update - May 11,2026Groundbreaking Update Drug: Alpha DaRTAnnounced Date: May 11, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced groundbreaking interim data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial.AI SummaryAlpha Tau Medical announced interim results from the REGAIN U.S. trial of Alpha DaRT for recurrent glioblastoma. In the first three patients treated at The Ohio State University Comprehensive Cancer Center, two achieved complete responses with total disappearance of all enhancing tumor lesions on multiple MRI scans. One grade 3 serious adverse event was reported but has since resolved. The procedures were performed by a multidisciplinary team led by principal investigator Joshua D. Palmer, MD, with medical physicist Michael Degnan, MS, DABR, and neurosurgeon J. Bradley Elder, MD, using a novel intracranial delivery approach designed by Alpha Tau. The REGAIN study is a prospective, open-label, single-arm trial evaluating the feasibility and safety of Alpha DaRT for recurrent GBM. The company noted that glioblastoma is highly aggressive and treatment-resistant, with an average survival of about eight months per the National Brain Tumor Society. Alpha Tau will hold a conference call with Dr. Palmer and management on May 11, 2026, at 8:30 am ET to discuss the data.Read Announcement
Enrollment Update - May 8,2026Enrollment Update Drug: Alpha DaRTAnnounced Date: May 8, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced the completion of enrollment in its ReSTART pivotal trial (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), a U.S. multicenter study evaluating the efficacy and safety of intratumoral Alpha DaRT for the treatment of patients with recurrent cutaneous squamous cell carcinoma (cSCC).AI SummaryAlpha Tau Medical Ltd. completed enrollment of 88 patients in ReSTART, a U.S. multicenter pivotal trial testing intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC). Completion shifts the study from recruitment to patient follow-up and data maturation, a key step toward assessing safety and effectiveness. Alpha DaRT inserts short-lived alpha-emitting sources directly into tumors. The particles act over very short distances, aiming to destroy cancer cells while sparing nearby healthy tissue. A pivotal trial is designed to provide the definitive clinical evidence regulators rely on. ReSTART builds on earlier skin cancer studies in Israel, Italy, France and the U.S. cSCC is the second most common skin cancer and is harder to treat when surgery and standard therapies fail. Alpha Tau, founded in 2016, focuses on developing Alpha DaRT for solid tumors and will now follow patients and analyze outcomes.Read Announcement
Presentation - May 4,2026Presentation Drug: Alpha DaRTAnnounced Date: May 4, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced the presentation of updated pooled results from two first-in-human clinical trials of Alpha DaRT in pancreatic ductal adenocarcinoma (PDAC) at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference.AI SummaryAlpha Tau Medical Ltd. presented pooled results from two first-in-human trials of Alpha DaRT in pancreatic ductal adenocarcinoma (PDAC) at Digestive Disease Week (DDW) 2026. The oral presentation marked the therapy’s first showing at a leading international gastroenterology conference. The pooled analysis showed a 100% local disease control rate in evaluable patients. Safety was favorable: among 26 treated subjects there were eight device-related adverse events in seven patients (27%), and all but one case (lingering fatigue) resolved within two weeks. Patients were highly heterogeneous and heavily pre-treated, including some ineligible for chemotherapy and others who had received up to four prior lines. Alpha DaRT is delivered via a streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed to fit standard GI endoscopy workflows. These initial human results suggest potential for patients with limited options and support further clinical study.Read Announcement
Provided Update - April 27,2026Provided Update Drug: Alpha DaRTAnnounced Date: April 27, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced that an abstract entitled "Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer" has been accepted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026. .AI SummaryAlpha Tau Medical Ltd. announced that an abstract titled "Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer" was accepted for presentation at the 2026 ASCO Annual Meeting, May 29–June 2, 2026. The pooled analysis reports safety and efficacy data from 58 patients enrolled in three prospective clinical studies conducted at centers in Canada and Israel. The abstract will be posted on the ASCO conference website on May 21, 2026 at 5:00 PM ET. The acceptance follows Alpha Tau presentations this year at the ASCO Gastrointestinal Cancers Symposium and Digestive Disease Week, signaling growing scientific interest in the company’s pancreatic cancer data. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an intratumoral alpha-emitter approach designed to deliver highly localized radiation to tumors while sparing nearby healthy tissue. Alpha Tau is developing this technology for the treatment of solid tumors. Read Announcement
Provided Update - April 23,2026Provided Update Drug: Alpha DaRTAnnounced Date: April 23, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced the successful treatment of the first patient in ACAPELLA (Alpha DaRT for CAncer of the PancrEas in Locally advanced Adenocarcinoma), the Company's European multicenter clinical trial evaluating Alpha DaRT combined with capecitabine for patients with inoperable locally advanced pancreatic ductal adenocarcinoma (LAPC) who have completed first-line mFOLFIRINOX chemotherapy..AI SummaryAlpha Tau Medical Ltd announced the successful treatment of the first patient in ACAPELLA, its European multicenter trial testing Alpha DaRT combined with capecitabine for people with inoperable, locally advanced pancreatic ductal adenocarcinoma (LAPC) who have completed first-line mFOLFIRINOX chemotherapy. Alpha DaRT delivers short-range alpha radiation from tiny radioactive sources implanted directly into the tumor using a minimally invasive technique. In ACAPELLA, Alpha DaRT is being given alongside oral capecitabine to see if the combination can better control tumors that cannot be removed by surgery. This first treatment marks the start of enrollment activity in the trial and is an early step toward evaluating safety, tolerability, and initial signals of effectiveness. The study is part of Alpha Tau’s broader effort to develop new local therapies for pancreatic cancer, a disease with limited treatment options and high unmet need. Follow-up will monitor tumor response and side effects over time. Read Announcement
Abstract - March 31,2026Abstract Drug: Alpha DaRTAnnounced Date: March 31, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference.AI SummaryAlpha Tau Medical Ltd. announced that an abstract reporting results from two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. The acceptance means the company's data will be shared in a main session at the global gastroenterology meeting May 2–5, 2026. The trials evaluated Alpha DaRT, Alpha Tau's targeted radiotherapy technology for solid tumors, and the oral slot suggests the findings are notable for clinicians and researchers. Alpha Tau, founded in 2016 in Israel, develops Alpha DaRT, which uses radioactive sources to treat tumors. Presenting at DDW gives the company exposure to specialists in gastroenterology, oncology and surgery and may help inform clinical practice and future research for pancreatic cancer — a disease with limited treatment options. Details of the trial outcomes will be revealed at the DDW presentation.Read Announcement
Results - January 6,2026Results Drug: Alpha DaRTAnnounced Date: January 6, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC).AI SummaryAlpha Tau Medical released final results from its first-in-human pancreatic cancer study in Montreal testing Alpha DaRT for pancreatic ductal adenocarcinoma (PDAC). In 32 patients (stage II–IV, many previously treated), Alpha DaRT delivered by endoscopic ultrasound was feasible and well tolerated. The trial showed a 22% objective response rate (ORR) and an 81% disease control rate (DCR); excluding the first two low-dose safety patients, ORR was 23% and DCR 87%. Results are published as abstracts and will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. In 23 patients with complete lab data, investigators saw no significant change one month after treatment in neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, CD4/CD8 T-cell ratio, or C-reactive protein, suggesting immune preservation versus typical radiation. IL-6 levels dropped dramatically (p<0.000001), indicating a possible anti-inflammatory effect. Alpha DaRT is now being studied with first-line chemotherapy in the U.S. multi-center IMPACT pilot trial (NCT06698458) for newly diagnosed unresectable or metastatic pancreatic cancer.Read Announcement
Provided Update - January 5,2026Provided Update Drug: Alpha DaRTAnnounced Date: January 5, 2026Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA's previous decision to allow the Company to use the more flexible modular approach.AI SummaryAlpha Tau Medical announced it submitted the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration for Alpha DaRT, its alpha-radiation therapy. The application seeks approval for treating recurrent cutaneous squamous cell carcinoma in patients who cannot have surgery or standard radiation and who have no curative systemic options. This initial module focuses on the required non-clinical study documentation. The FDA allowed Alpha Tau to use a modular PMA framework, which lets the company submit sections of the application over time. Alpha Tau says this flexible approach can enable ongoing FDA review and earlier feedback on each module, potentially speeding and clarifying the path toward authorization. The module was filed while Alpha Tau is running its ReSTART pivotal trial for recurrent cSCC. The company expects to finish recruiting patients for that study in the first quarter of 2026.Read Announcement
FDA approved - December 2,2025Fda Approved Drug: Alpha DaRTAnnounced Date: December 2, 2025Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with locally recurrent prostate cancer using the Company's Alpha DaRT technology.AI SummaryAlpha Tau Medical announced that the FDA has approved an Investigational Device Exemption (IDE) to start a U.S. pilot study using its Alpha DaRT technology to treat patients with locally recurrent prostate cancer. The company said the study will test Alpha DaRT as a focused local salvage therapy that could be an alternative to systemic androgen deprivation therapy. The trial plans to enroll up to 12 U.S. patients who have biochemical recurrence by the Phoenix definition (a PSA rise of 2 ng/mL from the PSA nadir). The primary goal is to evaluate safety, and secondary goals include assessing efficacy by biochemical and clinical measures of disease progression and overall survival. Alpha DaRT delivers radium-224–impregnated sources directly into tumors. Short-lived decay products emit high-energy alpha particles over very short distances, aiming to destroy tumor cells while limiting damage to nearby healthy tissue.Read Announcement
FDA Approval - April 2,2025Fda Approval Drug: Alpha DaRTAnnounced Date: April 2, 2025Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.AI SummaryAlpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) for a pilot study using its Alpha DaRT technology to treat patients with recurrent glioblastoma, an aggressive type of brain cancer. This new approach is aimed at patients whose tumors are not suitable for surgery and who have already received central nervous system radiation. The IDE approval enables the clinical trial to enroll up to ten U.S. patients and will focus on assessing the feasibility and safety of implanting the Alpha DaRT sources directly into the tumor. The Alpha DaRT method works by delivering radium-224 inside the tumor, allowing its decay to release high-energy alpha particles that target cancer cells while sparing healthy tissue. This pilot study marks an important step toward offering a new treatment option for patients facing the poor survival outcomes associated with recurrent glioblastoma.Read Announcement
FDA Approval - February 3,2025Fda Approval IDE ApplicationDrug: Alpha DaRTAnnounced Date: February 3, 2025Indication: Prostate cancerAnnouncementAlpha Tau Medical Ltd announced an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients.AI SummaryAlpha Tau Medical Ltd recently announced that the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplement. This supplement allows the company to expand its clinical trial for treating pancreatic cancer by combining its alpha-radiation therapy, Alpha DaRT®, with first-line chemotherapy. Originally, the clinical study focused on 12 patients with newly diagnosed metastatic pancreatic cancer. With the new FDA approval, the trial will now include an additional cohort of patients with locally advanced pancreatic cancer. Each cohort will be increased to 15 patients, resulting in a total of 30 patients across up to 10 U.S. clinical trial sites. This expansion brings Alpha Tau one step closer to studying the potential benefits of its innovative treatment across a broader range of pancreatic cancer patients.Read Announcement
